Success Metrics

Clinical Success Rate
57.1%

Based on 8 completed trials

Completion Rate
57%(8/14)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
6(40%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_3
6
40%
Ph phase_2
6
40%
Ph phase_1
2
13%

Phase Distribution

2

Early Stage

6

Mid Stage

6

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
6(40.0%)
Phase 3Large-scale testing
6(40.0%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

53.3%

8 of 15 finished

Non-Completion Rate

46.7%

7 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(8)
Terminated(7)

Detailed Status

Completed8
Terminated6
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (13.3%)
Phase 26 (40.0%)
Phase 36 (40.0%)
N/A1 (6.7%)

Trials by Status

terminated640%
completed853%
withdrawn17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_1

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626
withdrawnphase_2

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

NCT05178576
terminatedphase_3

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

NCT02375685
terminatedphase_3

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

NCT01965145
completedphase_1

Gevokizumab for Active Scleritis

NCT01835132
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT03798626Phase 1

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed
NCT05178576Phase 2

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Withdrawn
NCT02375685Phase 3

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

Terminated
NCT01965145Phase 3

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

Terminated
NCT01835132Phase 1

Gevokizumab for Active Scleritis

Completed
NCT02326740Phase 3

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Terminated
NCT02315417Phase 3

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Terminated
NCT02318914Phase 3

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Terminated
NCT01882504Phase 2

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Completed
NCT01950312Phase 2

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Completed
NCT02258867Phase 3

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Terminated
NCT02293564Not Applicable

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Completed
NCT01882491Phase 2

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Completed
NCT01683396Phase 2

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Completed
NCT01498874Phase 2

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15